Acorda Resubmits New Drug Application for Inbrija (CVT-301, levodopa inhalation powder)
ARDSLEY, N.Y.--(BUSINESS WIRE) December 7, 2017 -- Acorda Therapeutics (Nasdaq:ACOR) announced the resubmission of its New Drug Application (NDA) for Inbrija to the U.S. Food and Drug Administration (FDA). Inbrija is an investigational treatment for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 7, 2017 Category: Drugs & Pharmacology Source Type: news
Duopa (Carbidopa and Levodopa Enteral Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 13, 2017 Category: Drugs & Pharmacology Source Type: news
Carbidopa and Levodopa Extended Release Tablets (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 29, 2017 Category: Drugs & Pharmacology Source Type: news
Pancreatic cancer could be treated with a Parkinson's drug
Carbidopa, commonly used together with L-Dopa to treat Parkinson's disease, was found to stop tumor growth in mice and human cancer lines. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - September 29, 2017 Category: Neurology Tags: Pancreatic Cancer Source Type: news
Medical News Today: Pancreatic cancer could be treated with a Parkinson's drug
Carbidopa, commonly used together with L-Dopa to treat Parkinson's disease, was found to stop tumor growth in mice and human cancer lines. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 29, 2017 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news
Carbidopa and Levodopa Extended Release Tablets (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 27, 2017 Category: Drugs & Pharmacology Source Type: news
Calvin ’s gift: Second opinion provides answers and hope
It’s not often that parents breathe a sigh of relief when their child is diagnosed with a chronic, potentially debilitating condition. But that sense of peace is just what Paula and Scott Hurd felt when they were told that their son, Calvin, had a rare movement disorder. “We were so happy to finally understand what was happening,” says Paula.
Slipping away
The search for answers had begun several years earlier, when Calvin started limping. At first, his family thought he had simply tripped over something and injured himself. But when he didn’t improve, they took him to the doctor. A series of appointments with spe...
Source: Thrive, Children's Hospital Boston - September 13, 2017 Category: Pediatrics Authors: Jessica Cerretani Tags: Diseases & Conditions Our Patients’ Stories cerebral palsy Cerebral Palsy Program Dr. Benjamin Shore Dr. David Coulter dystonia Second opinion Source Type: news
Acorda Receives Refusal to File Letter from FDA for Inbrija (CVT-301, levodopa inhalation powder) New Drug Application
ARDSLEY, N.Y.--(BUSINESS WIRE)--August 29, 2017 -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 29, 2017 Category: Drugs & Pharmacology Source Type: news
Diabetes drug may be helpful for Parkinson's disease
Conclusion
This research shows some interesting early findings, though the magnitude of effect was very small compared to the improvements in symptoms with current dopaminergic drugs. The study was well conducted but did have some limitations:
The number of people taking part was quite small. This may have meant it was hard to detect any other benefits or harms of taking the drug other than the effects on motor scores.
The period of time people were given the drug and followed up meant that longer-term effects could not be measured.
The benefit of the drug observed so far might not be big enough to make a differen...
Source: NHS News Feed - August 4, 2017 Category: Consumer Health News Tags: Neurology Source Type: news
FDA Drug Safety Communication: Ongoing Safety Review of Stalevo (entacapone/carbidopa/levodopa) and possible development of Prostate Cancer
[03-31-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that may suggest that patients taking Stalevo, a Parkinson ' s disease medication, may be at an increased risk for developing prostate cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 3, 2017 Category: Drugs & Pharmacology Source Type: news
Acorda Submits New Drug Application to U.S. Food and Drug Administration for Inbrija (CVT-301, Levodopa Inhalation Powder)
ARDSLEY, N.Y.--(BUSINESS WIRE) June 29, 2017 -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Inbrija (CVT-301, levodopa inhalation powder). Acorda is... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 29, 2017 Category: Drugs & Pharmacology Source Type: news
Working Toward a World Without Parkinson ’s Disease
John L. Lehr is chief executive officer of the Parkinson’s Foundation. By John L. LehrNEW YORK, Jun 27 2017 (IPS)As one expert recently noted, if Parkinson’s were an infectious disease, we would call it an epidemic. Worldwide, 10 million people live with Parkinson’s disease, a number expected to double in the next 20 years. While there is no cure for Parkinson’s and no proven way to slow its progression, there is new reason to hope for a world without Parkinson’s. John L. LehrThe varied symptoms of Parkinson’s – including tremor, slowness, fatigue and cognitive difficulties – develop slowly and progress ove...
Source: IPS Inter Press Service - Health - June 27, 2017 Category: International Medicine & Public Health Authors: John Lehr Tags: Development & Aid Featured Global Headlines Health TerraViva United Nations Source Type: news
Quest to prevent Macular degeneration continues with UA researcher's $1.7m NIH grant
(University of Arizona Health Sciences) After showing that individuals who take levodopa, or l-dopa, for movement disorders such as Parkinson's disease are protected from developing macular degeneration, University of Arizona researcher Brian S. McKay, PhD, is taking the next step in his quest to prevent the blinding eye disease, thanks to a $1.7 million R01 grant from the National Eye Institute of the National Institutes of Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2017 Category: International Medicine & Public Health Source Type: news
Extended-Release Amantadine Effective for Dyskinesia in PD Extended-Release Amantadine Effective for Dyskinesia in PD
A phase 3 study shows a once-daily formulation of amantadine is superior to placebo in reducing severity and duration of levodopa-induced dyskinesia in patients with Parkinson ' s.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Drug reduces dyskinesia, 'off' times in Parkinson's patients
(Reuters Health) - An experimental extended-release version of the drug amantadine can reduce the duration of the involuntary dancing-like movements seen in people whose long-term use of levodopa has kept their Parkinson ’s disease under control. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
